Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)

This is an open-label, phase 2 study for lower risk MDS and high risk CCUS patients who are transfusion independent. There will be two cohorts enrolled at the same time to measure the effect of nicotinamide riboside and pterostilbene at different doses. The primary goals of the study are: * to assess if study drug improves cytopenias in patients * to determine safety of the study drug in patients

NCT Number	NCT07579429
Lead Sponsor	University of Colorado, Denver Collaborators: Cancer League of Colorado
Conditions	Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndrome
Enrollment	10 participants
Start Date	2026-05-20
Primary Completion	2029-12-18 (estimated)
Study Completion	2030-12-18 (estimated)
Updated on ClinicalTrials.gov	2026-06-03